BioMarin Pharmaceutical Inc., a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief Operations Officer, Robert J. Hombach, to its Board of Directors.
“We are thrilled to have Bob join BioMarin’s Board of Directors. He brings additional expertise in financial and operational management in the biopharmaceutical industry to an already outstanding board,” said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. “I am confident he will make meaningful contributions to support BioMarin’s growth as we continue to develop pioneering therapies for patients with rare genetic diseases.”
“I am honored to serve on the board of a company with a 20-year history of developing therapies that make a big difference for small patient populations,” said Robert J. Hombach. “I am looking forward to working with BioMarin as it continues to build its current business, while advancing a robust pipeline during a time of exceptional growth.”
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.